prikaz prve stranice dokumenta Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients
  Download
PDF 2.65 MB
master's thesis
Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients
Zagreb: University of Zagreb, Faculty of Science, 2022. urn:nbn:hr:217:579521
Lugar, Marija
University of Zagreb
Faculty of Science
Department of Biology

Institutional repository: Repository of the Faculty of Science

Cite this document

Lugar, M. (2022). Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients (Master's thesis). Zagreb: University of Zagreb, Faculty of Science. Retrieved from https://urn.nsk.hr/urn:nbn:hr:217:579521

Lugar, Marija. "Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients." Master's thesis, University of Zagreb, Faculty of Science, 2022. https://urn.nsk.hr/urn:nbn:hr:217:579521

Lugar, Marija. "Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients." Master's thesis, University of Zagreb, Faculty of Science, 2022. https://urn.nsk.hr/urn:nbn:hr:217:579521

Lugar, M. (2022). 'Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients', Master's thesis, University of Zagreb, Faculty of Science, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:217:579521

Lugar M. Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients [Master's thesis]. Zagreb: University of Zagreb, Faculty of Science; 2022 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:217:579521

M. Lugar, "Detection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients", Master's thesis, University of Zagreb, Faculty of Science, Zagreb, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:217:579521

Metadata
TitleDetection of autoantibodies specific for inflammation-associated proteins in COVID-19 patients
Title (croatian)Detekcija autoantitijela specifičnih za proteine upale kod oboljelih od bolesti COVID-19
AuthorMarija Lugar
MentorEzio Bonifacio (mentor)
MentorPetra Korać (sumentor)
Committee memberPetra Korać (predsjednik povjerenstva)
Committee memberZorana Grubić (član povjerenstva)
Committee memberDomagoj Đikić (član povjerenstva)
Committee memberInga Urlić (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Science
(Department of Biology)
Zagreb
Defense date and country2022-09-21, Croatia
Scientific / art field,
discipline and subdiscipline		NATURAL SCIENCES
Biology
Abstract
Coronavirus disease 2019 (COVID-19) manifests a variety of symptoms: from being asymptomatic or mild in most of the infected individuals, to causing more severe and even life-threatening conditions in about 20% of the patients. As an effector of the immune system and a hallmark of autoimmunity, autoantibodies are hypothesized to play a role in the pathogenesis of COVID-19 and pose a risk for a severe disease outcome. Hence, this thesis aimed to detect and investigate the prevalence of autoantibodies in sera from COVID-19 patients. Thereby, 100 hospitalized COVID-19 patients of different disease severity (42 moderate and 58 severe/critical) and 41 SARS-CoV-2 seronegative healthy blood donors were tested for autoantibodies specific for different inflammation-associated proteins (interferon (IFN), complement, and DDX helicases) by the luciferase immunoprecipitation system (LIPS) assay. The results show a high prevalence of autoantibodies measured in hospitalized COVID-19 patients (51%) in contrast to the control group (12.2%). However, only 8% of the patients had high and/or intermediate titers (IFN autoantibodies), whereas, in the remaining autoantibodypositive patients only low autoantibody titers were detected. Autoantibodies specific for complement proteins and DDX helicases were detected only in low titers. Interestingly, contrary to previous reports, no association with disease severity, sex, or age was observed for IFN autoantibodies. Overall, the findings suggest that from the measured autoantibodies, IFN autoantibodies could be a relevant prognostic marker in COVID-19, specifically for COVID-19 patients that require hospitalization. The findings emphasize the importance of a wider investigation of autoantibodies in COVID-19.
Abstract (croatian)
Bolest COVID-19 (od eng. coronavirus disease 2019) uključuje širok spektar simptoma: većina zaraženih pojedinaca nemaju simptome ili imaju blage simptome, dok se kod otprilike 20% slučajeva manifestira teški ili kritični oblik bolesti. Pretpostavlja se da autoantitijela, kao jedan od aktera imunosnog sustava te obilježje autoimunih bolesti, imaju ulogu u patogenezi bolesti COVID-19 te da predstavljaju rizik za razvoj težeg oblika bolesti. Glavni cilj ovog rada bio je detektirati autoantitijela kod bolesnika obljelih od bolesti COVID-19. Kako bi se ispitala prisutnost autoantitijela specifičnih za proteine upale (interferona (IFN), proteina komplementa te helikaze DEAD-box), uzorci 100 bolesnika obljelih od bolesti COVID-19, od toga 42 s umjerenim i 58 s težim/kritičnim oblikom bolesti, te 41 uzorak SARS-CoV-2 seronegativnih zdravih donora krvi testirani su na autoantitijela imunoprecipitacijskim testom luciferaze (LIPS, od eng. luciferaze immunoprecipitation system). Rezultati ukazuju na visoku prevalenciju autoantitijela kod hospitaliziranih bolesnika obljelih od bolesti COVID-19 (51%) u odnosu na kontrolnu skupinu (12.2%). Međutim, tek 8% pacijenata imalo je srednji ili visoki titar autoantitijela, isključivo specifičnih za IFN, dok je kod ostalih pacijenata pozitivnih na autoantitijela uočen tek nizak titar autoantitijela. Autoantitijela specifična za ostale testirane antigene sustava komplementa i helikaza DEAD-box detektirana su u vrlo niskom titru. Zanimljivo je da suprotno rezultatima prijašnjih studija, u ovom radu nije uočena povezanost IFN autoantitijela s dobi, spolom ili težinom bolesti. Rezultati ukazuju da od testiranih autoantitijela, jedino ona specifična za interferone mogu biti potencijalni marker bolesti COVID-19, posebice za hospitalizirane pacijente. Ovi rezultati pridodaju važnosti šireg istraživanja autoantitijela kod oboljelih od bolesti COVID-19.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:217:579521
Study programmeTitle: Molecular Biology
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra molekularne biologije (magistar/magistra molekularne biologije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2024-09-21
Terms of useLicence In copyright icon
Created on2022-10-25 11:44:46